Results 91 to 100 of about 9,195 (133)

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects. [PDF]

Clin Pharmacol Drug Dev
Gonzalez M, Yang Z, Schelman WR, Zhou X, Gupta N, Chien C.   +5 more
europepmc   +1 more source

Biomarkers for exposure and for the effects of contamination with polyhalogenated aromatic hydrocarbons in Baltic ringed and grey seals [PDF]

, 2000
Nyman, Madeleine
core  

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies. [PDF]

Clin Pharmacol Drug Dev
Chen Y, Teng R, Szanto A, Kapopara A, Bannerji R, Ogier J, Mahalingam D.   +6 more
europepmc   +1 more source

Canine duodenal organoids as a functional platform for intestinal CYP regulation and drug metabolism studies. [PDF]

Drug Metab Dispos
Nakazawa M, Court MH, Ambrosini YM.
europepmc   +1 more source

Dual effects of indoxyl sulfate on modulation of human hepatic CYP3A activity, with individual differences. [PDF]

PLoS One
Togao M, Asakawa N, Wagai G, Ohta-Takada Y, Otsuka J, Ando M, Kurita A, Kawakami K.   +7 more
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P-Glycoprotein Inhibition. [PDF]

Clin Pharmacol Drug Dev
Jia H, Ballard TE, Zhang L, Cohen L, Bergagnini-Kolev MC, Templeton IE, Jones HM, Yin W.   +7 more
europepmc   +1 more source

Cyp3a4-Mediated in vitro Metabolism and in vivo Disposition of Lorlatinib in Rats. [PDF]

Drug Des Devel Ther
Xie C, Guan T, Huang J, Chen J, Li Y, Zheng P.   +5 more
europepmc   +1 more source

Pharmacokinetics of midazolam and hepatic cytochrome P450 3A activity in an in vivo extracorporeal membrane oxygenation rat model. [PDF]

Sci Rep
Sato Y, Motoishi E, Kakuba R, Nagatsuka Y, Abe T, Fujii Y.   +5 more
europepmc   +1 more source

Drug-drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450. [PDF]

Br J Clin Pharmacol
Purohit VS, Huh Y, Dowty ME, Plotka A, Lejeune A, Kalluru H, Hee B.   +6 more
europepmc   +1 more source

Clinical Evaluation of Drug-Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P-gp Pathways. [PDF]

J Clin Pharmacol
Arora P, Liu H, Ling J, Hindman JT, Marathe DD.   +4 more
europepmc   +1 more source